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B R I E F R E P O R T
Switch to Raltegravir From Protease
Inhibitor or Nonnucleoside Reverse-
Transcriptase Inhibitor Does not
Reduce Visceral Fat In Human
Immunodeficiency Virus-Infected
Women With Central Adiposity
Jordan E. Lake,1 Grace A. McComsey,2 Todd Hulgan,3 Christine A. Wanke,4
Alexandra Mangili,4 Sharon L. Walmsley,5 and Judith S. Currier1
1Department of Medicine, University of California, Los Angeles, California;
2Department of Pediatrics and Medicine, Case Western Reserve University,
Cleveland, Ohio; 3Department of Medicine, Vanderbilt University, Nashville,
Tennessee; 4Department of Medicine, Tufts University, Boston, Massachusetts; and
5Department of Medicine, University of Toronto, Ontario, Canada
Human immunodeficiency virus-infected women with cen-
tral adiposity switched to raltegravir-based antiretroviral
therapy immediately or after 24 weeks. No statistically signif-
icant changes in computed tomography-quantified visceral
adipose tissue (VAT) or subcutaneous fat were observed, al-
though 48 weeks of raltegravir was associated with a 6.4%
VAT decline. Raltegravir for 24 weeks was associated with im-
provements in lipids.
Keywords. antiretroviral therapy; fat; HIV; raltegravir;
visceral; women.
High rates of central adiposity and generalized obesity have
been reported in human immunodeficiency virus-infected
(HIV+) persons on antiretroviral therapy (ART) [1, 2]. Antire-
troviral therapy-related adipose tissue (AT) accumulation in the
trunk and viscera (lipohypertrophy) may be more common in
HIV+ women [3, 4]; however, the contribution of specific anti-
retroviral agents and the efficacy of switching ART to improve
lipohypertrophy remain unclear.
We previously reported 24-week results from a randomized
clinical trial of switch to raltegravir (RAL)-based ART versus
continued protease inhibitor (PI)-based or nonnucleoside re-
verse-transcriptase inhibitor (NNRTI)-based therapy in HIV+
women with central adiposity on suppressive ART. No statisti-
cally significant between-group changes in visceral AT (VAT) or
abdominal subcutaneous AT (SAT) were observed, although
RAL-treated participants experienced significant reductions in
low-density lipoprotein (LDL) and total cholesterol levels [5].
We now report the final, 48-week results from this trial.
METHODS
Patient Population
Complete enrollment procedures have been described previously
[5]. Participants were recruited from 5 North American centers
from September 2008 to July 2010, with 48-week follow-up
completed in June 2011. All study documents and procedures
were approved by the institutional review boards or ethics
committees of the participating institutions. All participants pro-
vided written informed consent before initiation of study proce-
dures. This trial is registered at clinicaltrials.gov (NCT00656175).
Study Design
Participants were randomized 1:1 to continue their NRTIs but
switched from PI or NNRTI to open label RAL 400 mg twice
daily by mouth at Week 0 (immediate) or 24 (delayed). Delayed-
switch participants provided an internal control group for the first
24 weeks. During Weeks 24–48, all participants received RAL.
The primary endpoint was between-group change in percent-
age of VAT 24 weeks after switch to RAL versus continued PI/
NNRTI. Sample size was informed by the US Food and Drug
Administration, which defined a ≥8% between-group VAT
change as clinically significant [6]. Eighteen women per
randomized group provided 80% power to detect a 10% be-
tween-group VAT difference at 24 weeks. Secondary endpoints
included 48-week follow-up of immediate-switch participants,
24-week (Weeks 24–48) follow-up of delayed-switch partici-
pants, 24-week pooled follow-up of all participants (Weeks
0–24 for immediate-switch, Weeks 24–48 for delayed-switch),
and measurement of fasting lipids, glucose, and high-sensitivity
C-reactive protein (hs-CRP). A Data Safety Monitoring Board
performed quarterly reviews without interim data analyses.
Assessments
Adipose tissue areas (VAT, SAT, and total AT [TAT]) were mea-
sured via single slice L4-L5 computed tomography (CT) scan at
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Weeks 0, 24, and 48. Scans were performed locally but read cen-
trally by a blinded reader at the Tufts University Body Compo-
sition Center. Site phantom scans were analyzed by the reading
center before initiation of study procedures to ensure between-
site scan consistency.
Fasting (>8 hours) glucose, lipoprotein profile, hs-CRP, CD4+
T lymphocyte counts, HIV-1 RNA (assay sensitivity ≤50 cop-
ies/mL), and safety evaluations (complete blood count with dif-
ferential, liver enzymes, serum creatinine, pregnancy test) were
measured as per the schedule of events [5]. Laboratory tests
were performed in real time and according to local standards.
Adverse events were graded using the Division of AIDS
Table for Grading the Severity of Adult and Pediatric Adverse
Events (Version 1.0, December 2004). All Grade ≥3 clinical
events and ≥2 laboratory abnormalities were reported to the
Data Management Center, as required.
Statistical Analysis
Baseline characteristics were compared using the Mann–
Whitney U test and Fisher’s exact test for continuous and cate-
gorical variables, respectively. Medians and interquartile ranges
are reported for continuous variables, and percentages are
Table 1. Baseline Demographic and Clinical Characteristicsa
Immediate Delayed Overall
Ethnicity n = 17 n = 20 n = 37
African American 53% 65% 59%
Hispanic 23% 10% 16%
White 18% 25% 22%
Asian 6% 0% 3%
Age (years) 41 (39, 47) 46 (36, 51) 43 (37, 49)
BMI (kg/m2) 34.7 (28.8, 37.6) 30.4 (27.7, 35.4) 32.0 (28.0, 36.5)
Tobacco use (current)b 24% 60% 43%
CD4+ T Lymphocyte count (cells/mm3) 563 (447, 747) 554 (354, 770) 558 (422, 747)
Time on ART (years) 5.1 (3.1, 7.1) 2.7 (1.6, 6.3) 3.7 (2.4, 7.1)
PI n = 11 (65%) n = 12 (60%) n = 23 (62%)
Atazanavir/ritonavir 35% 30% 32%
Atazanavir 6% 15% 11%
Fosamprenavir/ritonavir 0% 5% 3%
Fosamprenavir 0% 5% 3%
Lopinavir/ritonavir 18% 5% 11%
Nelfinavir 6% 0% 3%
NNRTI n = 6 (35%) n = 8 (40%) n = 14 (38%)
Efavirenz 18% 30% 24%
Etravirine 6% 0% 3%
Nevirapine 12% 10% 11%
NRTI n = 17 (100%) n = 20 (100%) n = 37 (100%)
Abacavir 18% 25% 22%
Lamivudine 29% 35% 32%
Emtricitabine 71% 65% 68%
Tenofovir 82% 75% 78%
Glucose (mg/dL) 84.0 (78.0, 93.0) 88.5 (80.0, 97.5) 87.0 (78.0, 94.0)
Total cholesterol (mg/dL) 179.0 (162.0, 206.0) 199.0 (164.5, 221.5) 188.0 (162.0, 214.0)
Triglycerides (mg/dL) 116.0 (85.0, 144.0) 129.0 (101.0, 176.0) 118.0 (92.0, 152.0)
LDL (mg/dL) 113.0 (103.0, 123.0) 116 (89.0, 138.1) 115.8 (93.0, 128.0)
HDL (mg/dL) 47.6 (40.2, 57.0) 49.1 (39.0, 55.0) 49.0 (40.0, 57.0)
hs-CRP (mg/dL) 2.7 (0.6, 6.0) 4.7 (0.8, 7.5) 3.2 (0.6, 6.5)
Diabetesc 0% 0% 0%
Hyperlipidemiac 18% 25% 22%
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HDL, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL, low-
density lipoprotein cholesterol; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a Percentage or median with interquartile range. Mann–WhitneyU or Fisher’s exact tests used to test statistical significance for continuous and categorical variables,
respectively.
b P = .05. Otherwise, no statistically significant association between-arm differences.
c Defined as self-reported diagnosis or on-therapy at baseline.
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reported for categorical data. Comparison of median within- and
between-group change scores was performed using the Wilcoxon
signed-rank test. The primary analysis was as-treated, excluding
participants who did not remain on study drug or have an ob-
served primary endpoint. Supplemental intent-to-treat and log-
transformed mean value analyses produced similar results (data
not shown). Nonprotocol-defined secondary analyses included
stratification by body mass index ([BMI] <30 vs ≥30 kg/m2)
and entry ART regimen (PI vs NNRTI). Linear regression as-
sessed confounding effects (age <50 vs ≥50 years, randomization
arm, entry ART class, study site, smoking status), but it did not
provide additional insight (data not shown). All statistical tests
were 2-sided (α = 0.05) without adjustment for multiple testing.
Week 0, 24, and 48 CT scans were not performed on the same
scanner for all participants, but phantom scan comparison and
sensitivity analysis confirmed that discrepancies were minimal
and required no additional statistical correction. Data analysis
and management were performed using SAS 9.2 (SAS Institute,
Inc., Cary, NC).
RESULTS
Thirty-nine participants enrolled in the study: 37 completedWeek
24, 36 completed Week 48, and 1 participant was excluded after
Week 24 [5].Complete baseline characteristics have been described
previously [5]. Seventeen participants randomized to immediate-
switch, and 20 participants randomized to delayed-switch. Ran-
domized groups were well balanced, except for higher current
smoking rates among delayed-switch women (60% vs 24%,
P < .05; Table 1). The median age was 43 years, BMI was 32 kg/
m2, 75% of participants were non-white, 62% were PI-treated
(83% ritonavir-boosted), and the most commonNRTIs were teno-
fovir (59%) and emtricitabine (49%). No adverse events occurred.
After 48 weeks, no statistically significant changes in AT or
BMI occurred among immediate-switch participants, and the
initially observed LDL cholesterol decline did not remain signif-
icant (Table 2). However, a nonsignificant VAT decline (−6.4%,
P = .85) and a significant hs-CRP decline (−1.0 mg/L, P = .02)
were observed. No significant differences in 48-week findings
were observed by entry ART regimen.
In the delayed-switch arm, switch to RAL at Week 24 was as-
sociated with an increase in the percentage of SAT (3.4%,
P = .05) and BMI (0.6 kg/m2, P = .05). Significant declines in
total cholesterol, LDL cholesterol, and high-density lipoprotein
cholesterol were observed, with a trend seen for triglycerides.
Unlike immediate-switch participants [5], lipid declines after
switch to RAL seemed to be driven by switch from NNRTI rath-
er than PI, although participant numbers were small in this sub-
group analysis. A similar phenomenon was observed for SAT
(PI: −0.1%, P = .52; NNRTI: 8.8%, P = .05).
Table 2. Median Changes in Adipose Tissue, Anthropometrics, and Laboratory Values After Switch to Raltegravir
Week 0–48 Changes Week 24–48 Changes Pooled 24-Week Changes
Immediate
Within-
Group
P Value Delayed
Within-
Group
P Value
Immediate
0–24 wks
Delayed 24–48 wks
Within-
Group
P Value
N 17 19 36
BMI (kg/m2) −0.1 (−0.9, 0.4) .52 0.6 (0.0, 1.6) .05 0.3 (−0.2, 1.1) .05
Waist-to-hip ratio −0.01 (−0.04, 0.02) .24 0.0 (−0.02, 0.01) .47 0.0 (−0.02, 0.02) .50
TAT (cm2) −16.5 (−52.5, 17.2) .40 26.5 (−24.7, 31.0) .28 8.9 (−33.6, 30.1) 1.00
SAT (cm2) −17.8 (−30.3, 28.) .57 13.4 (−5.2, 36.0) .10 0.8 (−26.0, 31.6) .59
VAT (cm2) −11.7 (−17.4, 13.3) .68 −2.8 (−18.9, 11.1) .64 −4.4 (−18.9, 13.1) .51
VAT/SAT −0.01 (−0.04, 0.04) .86 −0.01 (−0.06, 0.01) .23 −0.02 (−0.05, 0.02) .30
VAT/TAT −0.01 (−0.02, 0.03) .96 0.0 (−0.03, 0.01) .26 0.01 (−0.03, 0.01) .30
%VAT change −6.4 (−15.6, 12.5) .85 −1.8 (−12.3, 11.4) .70 −3.3 (−12.3, 12.1) .60
%SAT change −2.9 (−9.7, 5.9) .46 3.4 (−1.4, 9.4) .05 −5.6 (7.2, 0.4) .47
CD4+ T Lymphocyte count (cells/
mm3)
46.0 (−10.0, 61.0) .16 42.0 (−26.0, 133.0) .08 5.0 (−29.0, 62.0) .27
Glucose (mg/dL) 4.0 (0.0, 8.0) .13 0.5 (−6.0, 5.0) .85 0.0 (−6.0, 5.0) .70
Total cholesterol (mg/dL) −14.0 (−29.0, 6.0) .01 −20.0 (−47.0, −2.0) <.001 −17.0 (−31.0, −2.0) <.0001
Triglycerides (mg/dL) −1.0 (−21.0, 9.0) .32 −27.5 (−42.0, 8.0) .07 −18.0 (−42.0, 8.0) <.01
LDL cholesterol (mg/dL) −2.0 (−28.8, 3.2) .16 −6.2 (−23.0, 0.0) .01 −9.1 (−23.9, 1.6) <.01
HDL cholesterol (mg/dL) −4.0 (−9.6, 3.0) .25 −4.3 (−6.0, −1.0) .03 −2.6 (−6.0, 0.4) .03
hs-CRP (mg/L) −1.0 (3.2, 0.0) .02 −0.4 (−1.4, 2.2) 1.00 −0.2 (−1.9, 0.5) .34
Bold text represents statistically significant findings (P≤ .05).
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; SAT, subcutaneous
adipose tissue; TAT, total adipose tissue; VAT, visceral adipose tissue.
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In a pooled analysis of 24-week data after switch to RAL (Weeks
0–24 for immediate-switch, Weeks 24–48 for delayed-switch), a
significant BMI increase (0.3 kg/m2, P = .05) was observed that
was driven by switch from NNRTI (0.7 kg/m2, P = .03) versus PI
(0.2 kg/m2, P = .56; between-group, P = .08). Of note, no signifi-
cant AT changes accompanied the observed BMI change. Signifi-
cant declines in all lipid parameters were also observed, but lipid
changes did not vary significantly by entry ART type.
DISCUSSION
No statistically significant AT changes were observed 24 or 48
weeks after switch to RAL in this group of HIV+ women with
central adiposity on suppressive ART. Although not statistically
significant (given our power to detect a ≥10% change), women
receiving RAL for 48 weeks did experience a 6.4% median VAT
decline that was progressive throughout the 48-week observation
period. Because VAT changes of as little as 5% are believed to af-
fect risk for metabolic syndrome [7], the 6.4% observed VAT de-
cline could have an associated clinical benefit. Supporting this
hypothesis is the 48-week hs-CRP decline also observed in this
group. Larger studies with longer follow-up time are needed to
determine whether this finding can be confirmed, whether con-
tinued VAT improvements are seen with longer RAL exposure,
and/or whether an associated clinical benefit can be defined.
Switch to RAL was also associated with significant lipid de-
clines that occurred in both PI- and NNRTI-treated women. Al-
though lipid reductions have previously been reported after
switch from PI- and NNRTI-based therapy to RAL [8–13],
our study is the first to specifically report this finding among
women, many with generalized obesity, and to definitively re-
port similar lipid declines among women switching from PI
and NNRTI.
Finally, we observed small increases in TAT, SAT, and BMI in
the delayed-switch group and BMI in the pooled analysis that ap-
peared to be driven by switch from NNRTI to RAL. These AT
increases in delayed-switch participants differ from the declines
originally observed among immediate-switch women 24 weeks
after switch to RAL [5]. An obvious physiologic explanation is
not apparent, but these AT changes were small, may not be clin-
ically significant, and, except for BMI, did not reach statistical sig-
nificance. In addition, the BMI increase in the pooled analysis
(which was accompanied by a nonsignificant SAT decrease)
could result from an increase in lean mass, which we were unable
to assess. More importantly, BMI increases after switch to RAL
have only previously been reported in persons switching for viro-
logic failure or from thymidine analog NRTI [14, 15].
CONCLUSIONS
This study has several limitations, most notably is a small sam-
ple size, which increases the risk of type II error and prevents
measurement of small but potentially clinically significant VAT
changes. In addition, the study was not powered to look at sub-
groups, and, although the pooled 24-week analysis improved
power to assess some endpoints, results may be confounded by
the time lag between switches to RAL. Finally, some women
had generalized obesity (rather than isolated lipohypertrophy),
which could not be expected to improve with ART switch. De-
spite these limitations, results from this randomized controlled
trial provide important insight into the use of RAL in women
on PI- and NNRTI-based ART. Although switch to RAL was
not associated with statistically significant improvements in cen-
tral adiposity in this study, the small observed VAT and hs-CRP
decline after 48 weeks of RAL, and the significant lipid declines
may be useful in minimizing cardiovascular risk, particularly in
the growing, obese HIV+ population.
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